Betancor Gilberto
Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Canary Islands, Spain.
Vaccines (Basel). 2023 May 3;11(5):930. doi: 10.3390/vaccines11050930.
Myxovirus resistance (MX) proteins are pivotal players in the innate immune response to viral infections. Less than 10 years ago, three independent groups simultaneously showed that human MX2 is an interferon (IFN)-stimulated gene (ISG) with potent anti-human immunodeficiency virus 1 (HIV-1) activity. Thenceforth, multiple research works have been published highlighting the ability of MX2 to inhibit RNA and DNA viruses. These growing bodies of evidence have identified some of the key determinants regulating its antiviral activity. Therefore, the importance of the protein amino-terminal domain, the oligomerization state, or the ability to interact with viral components is now well recognized. Nonetheless, there are still several unknown aspects of MX2 antiviral activity asking for further research, such as the role of cellular localization or the effect of post-translational modifications. This work aims to provide a comprehensive review of our current knowledge on the molecular determinants governing the antiviral activity of this versatile ISG, using human MX2 and HIV-1 inhibition as a reference, but drawing parallelisms and noting divergent mechanisms with other proteins and viruses when necessary.
黏液病毒抗性(MX)蛋白是病毒感染先天免疫反应中的关键参与者。不到10年前,三个独立的研究小组同时表明,人类MX2是一种具有强大抗人类免疫缺陷病毒1(HIV-1)活性的干扰素(IFN)刺激基因(ISG)。从那时起,多项研究工作相继发表,突出了MX2抑制RNA和DNA病毒的能力。这些越来越多的证据已经确定了一些调节其抗病毒活性的关键决定因素。因此,蛋白质氨基末端结构域、寡聚化状态或与病毒成分相互作用的能力的重要性现在已得到充分认识。尽管如此,MX2抗病毒活性仍有几个未知方面需要进一步研究,例如细胞定位的作用或翻译后修饰的影响。这项工作旨在全面综述我们目前对这种多功能ISG抗病毒活性分子决定因素的认识,以人类MX2和HIV-1抑制为参考,但必要时与其他蛋白质和病毒进行比较并指出不同的机制。